Dachsous Inhibitors

Dachsous inhibitors employ a myriad of biochemical strategies to modify the functional behavior and localization of the dachsous protein. For example, LY294002 is a PI3K inhibitor that curtails the PI3K-Akt signaling pathway, thereby downregulating the expression of dachsous at the transcriptional level. Wortmannin, another PI3K inhibitor, functions similarly by suppressing the PI3K-Akt pathway, which has a downstream impact on both dachsous transcription and protein stabilization. On the other hand, Wnt-C59 and IWP-2 are Porcupine inhibitors that halt Wnt ligand secretion. This affects the interaction between Wnt, Frizzled, and dachsous, which is crucial for establishing cell polarity. Tankyrase inhibitors like XAV939 function by stabilizing axin. This disrupts the Wnt/β-catenin signaling pathway, impacting the localization and function of dachsous. SP600125, a JNK inhibitor, targets the JNK-c-Jun signaling axis, altering the phosphorylation and subsequent localization of dachsous. TGF-beta inhibitors such as SB431542 act by suppressing SMAD2/3 signaling, causing a reduction in dachsous expression levels. Casein kinase inhibitors like CKI-7, FGFR inhibitors like PD173074, and myosin II inhibitors like Blebbistatin exert their effects through distinct pathways that, while not directly involving dachsous, modulate its function and localization indirectly through changes in cytoskeletal dynamics or protein-protein interactions.